drugset / Trial / NCT01612260
Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
Phase 4
Unknown
460 enrolled
Cong-xin Huang
Chinese Academy of Medical Sciences, Fuwai Hospital · collabFudan University · collabNanjing Medical University · collabShanghai Changzheng Hospital · collabThird Military Medical University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the effects of Chinese medicine Shensong Yangxin capsule for the chronic cardiac dysfunction complicated with ventricular premature beats.
Timeline
- Start
- 2012-09
- Primary completion
- 2013-08
- Completion
- 2013-12
Outcome
Met primary endpoint
paper SSYX caused a significantly greater decline in the total number of VPCs than the placebo did PMID 28685712 ↗
paper (-2145 ± 2848 vs. -841 ± 3411, P < 0.05). PMID 28685712 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Shensong Yangxin capsule | Traditional medicine (herbal / TCM) | 4 unknown | Oral |